Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mineralys Therapeutics, Inc.

15.02
+0.53003.66%
Post-market: 15.020.00000.00%17:42 EDT
Volume:518.96K
Turnover:7.73M
Market Cap:978.93M
PE:-4.03
High:15.17
Open:14.20
Low:14.07
Close:14.49
Loading ...

Mineralys Therapeutics, Inc. (MLYS) Receives a Hold from Jefferies

TIPRANKS
·
Yesterday

Mineralys Therapeutics Announces Journal of the American Medical Association (Jama) Publication of Pivotal Phase 3 Launch-Htn Trial for Lorundrostat

THOMSON REUTERS
·
30 Jun

Mineralys Therapeutics Inc: Lorundrostat Was Generally Well-Tolerated

THOMSON REUTERS
·
30 Jun

Mineralys Therapeutics Announces Positive Results from Phase 2 Explore-CKD Trial of Lorundrostat for Hypertension Treatment

Reuters
·
17 Jun

Mineralys Therapeutics Announces Positive Topline Results From Phase 2 Explore-Ckd Trial of Lorundrostat for the Treatment of Hypertension in Subjects With Ckd and Albuminuria

THOMSON REUTERS
·
17 Jun

Mineralys Therapeutics Inc - One Subject Discontinued Lorundrostat Due to Elevated Potassium

THOMSON REUTERS
·
17 Jun

Mineralys Therapeutics Inc - Serious Adverse Events Reported in 3% of Subjects During Lorundrostat Treatment

THOMSON REUTERS
·
17 Jun

Mineralys Therapeutics Inc - Lorundrostat Shows 31% Reduction in Urine Albumin-to-Creatinine Ratio

THOMSON REUTERS
·
17 Jun

Mineralys Therapeutics Inc - Lorundrostat 25 Mg Achieves 9.3 Mmhg Reduction in Systolic Blood Pressure

THOMSON REUTERS
·
17 Jun

Mineralys Therapeutics Inc - Lorundrostat Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
17 Jun

Mineralys Therapeutics Inc. Chief Medical Officer David Rodman Reports Disposal of Common Shares

Reuters
·
17 Jun

Jefferies Initiates Coverage on Mineralys Therapeutics With Hold Rating, $15 Price Target

MT Newswires Live
·
11 Jun

Cautious Outlook for Mineralys Therapeutics Amid Market Challenges and Competitive Pressures

TIPRANKS
·
11 Jun

Mineralys announces late-breaking presentation of data from Launch-HTN trial

TIPRANKS
·
26 May

BRIEF-Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12

Reuters
·
24 May

Mineralys Therapeutics Inc - Lorundrostat Shows 16.9 Mmhg Reduction at Week 6, 19.0 Mmhg at Week 12

THOMSON REUTERS
·
24 May

Mineralys Therapeutics Inc - Trial Met Endpoints With Significant Blood Pressure Reduction

THOMSON REUTERS
·
24 May

Mineralys Therapeutics Inc - Lorundrostat Safety Profile Shows Modest, Reversible Effects on Electrolytes

THOMSON REUTERS
·
24 May

Mineralys Therapeutics Inc. Conducted Annual Stockholder Meeting

Reuters
·
23 May

BRIEF-Mineralys Announces Late-Breaking Presentation Of Phase 3 Launch-HTN Trial

Reuters
·
20 May